Association of Apolipoprotein E Polymorphism with Adipokines and Cardiovascular Disease Risk in Rheumatoid Arthritis Patients.
Yi Ming ChenPo-Ku ChenChing-Kun ChangChi-Chien LinHsin-Hua ChenJoung-Liang LanShih-Hsin ChangDer-Yuan ChenPublished in: Life (Basel, Switzerland) (2020)
Apolipoprotein E (ApoE) polymorphism and adipokines are linked to atherosclerosis. We aimed to investigate the associations of apoE genotypes with adipokines, inflammatory parameters, and cardiovascular disease (CVD) risks in rheumatoid arthritis (RA) patients. We enrolled 152 RA patients and 49 healthy control (HC) subjects. The apoE genotyping was determined by a polymerase chain reaction, while plasma levels of adipokines and inflammatory cytokines were measured with ELISA. Although apoE genotypes distributions were indistinguishable between RA patients and HC, we found significantly higher levels of apoE and adipokines in RA patients compared with HC. RA patients with ε2ε3 genotype had lower levels of TNF-α, IL-6, resistin, and visfatin, but higher leptin levels compared with ε3ε3 genotype patients. Patients with ε3ε4 genotype had significantly higher low-density lipoprotein-cholesterol (LDL-C) levels and atherogenic index scores compared with ε2ε3 genotype carriers. Moreover, patients with ε2ε3 genotype had significantly lower 10-year CVD risk than ε3ε3 or ε3ε4 genotype patients. ε3ε4 genotype and adiponectin levels were independent predictors of a high 10-year CVD risk. RA patients with ε2ε3 genotype are associated with lower levels of TNF-α, IL-6, resistin, visfatin, and CVD risk, while RA patients with ε3ε4 genotype exhibited higher levels of LDL-C, insulin resistance, and higher CVD risks.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- cardiovascular disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- insulin resistance
- disease activity
- high fat diet
- type diabetes
- cognitive decline
- adipose tissue
- ankylosing spondylitis
- gene expression
- oxidative stress
- risk assessment
- patient reported outcomes
- dna methylation
- high throughput
- idiopathic pulmonary fibrosis
- monoclonal antibody
- low density lipoprotein